ReviewJournal of immunology research2026
Tfh Cells in Henoch-Schönlein Purpura (IgA Vasculitis): Current Concept.
Review in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tfh Cells in Henoch-Schönlein Purpura (IgA Vasculitis): Current Concept.Journal of immunology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Henoch-Schönlein purpura (HSP) is an inflammatory condition affecting the small blood vessels, leading to organ damage and symptoms across various body systems, including skin, joints, and kidneys. The disease's pathogenesis involves the deposition of immunoglobulin (Ig) A immune complexes in vessels, triggering inflammation and damage. Recent research highlights the role of T follicular helper cells (Tfh cells) in HSP. The review delves into Tfh cells' biological functions, emphasizing their involvement in the HSP's development by activating autoreactive B cells and inducing the production of autoantibodies through the secretion of interleukin (IL)-21, IL-4, and IL-6. Additionally, the roles of different Tfh cell subsets in the pathogenesis of HSP are also characterized by their unique features. We also highlight the relationship between Tfh cells and galactose-deficient IgA1 (Gd-IgA1) production, compare Tfh-mediated immune responses in HSP with those in IgA nephropathy (IgAN) and systemic lupus erythematosus (SLE), and discuss emerging therapeutic strategies targeting the Tfh-B-cell axis. It concludes by suggesting the need for further research on Tfh cells to understand HSP pathogenesis better and develop effective treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.